Clinical trials: Invasive Breast Carcinoma
Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
The goals of this prospective, observational cohort study are to determine the feasibility of implementing paclitaxel therapeutic drug monitoring for cancer patients and explore the relationship between paclitaxel drug exposure…
- Conditions
- Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Cervical Carcinoma
- Trial name
- NCT03987555
- Testing
- Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer Invasive
Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery
In this project, the investigators will develop novel optical coherence tomography (OCT)-Raman spectroscopy and autofluorescence (AF)-Raman spectroscopy systems based on a selective sampling approach optimised for high-resolution…
- Trial name
- NCT06977698
- Testing
- OCT-Raman, AF-Raman
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- University of Nottingham
Breast Cancer, Breast Carcinoma in Situ
Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value)
The study aspires to provide outcomes on surgery, quality of life and time-to-event outcomes following the development and validation of a standardised surgical assessment tool in a shared decision-making framework for patients…
- Conditions
- Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Invasive, Breast Asymmetry
- Trial name
- OncoPROValue-1 (NCT06401304)
- Where
- 3 sites in Australia, Sweden and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Uppsala University
Breast Cancer
Study Into the Use of Electrical Impedance Mammography in the Diagnosis and Characterisation of Breast Disease
The Signascan Electrical Impedance Mammography (EIM) Study is a pilot study of a non-invasive medical device - a novel approach to breast cancer detection using Electrical Impedance Mammography (passing minute electrical currents…
- Trial name
- Signascan (NCT01217489)
- Testing
- Breast scan - Electrical Impedance Mammography
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Oxford University Hospitals NHS Trust
Invasive Breast Cancer
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
This study is being done to test the safety and effectiveness of two drugs, Anastrozole and Fulvestrant, used as combined therapy in the neo-adjuvant setting for hormone receptor positive invasive breast cancer.
- Trial name
- NCT00921115
- Testing
- Fulvestrant, Anastrazole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Kansas Medical Center
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
- Trial name
- LoTam (NCT06671912)
- Testing
- Anastrozole, Letrozole, Exemestane
- Where
- 732 sites in United States, Puerto Rico
- Volunteers
- 1,556 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
This phase Ib trials studies the side effects and how well talimogene laherparepvec works when given together with chemotherapy or endocrine therapy in treating patients with breast cancer that does not express the human…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT03554044
- Testing
- Anastrozole, Exemestane, Fulvestrant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Triple-Negative Invasive Breast Carcinoma, Residual Tumor
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. Its incidence is approximately 180,000 cases per year.
- Trial name
- NCT02670109
- Testing
- Carmustine, Cyclophosphamide, Carboplatin
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Breast Cancer, Invasive Ductal
Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer
The purpose of the study is to evaluate the efficacy of a dedicated Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) unit in ablating breast cancer by comparing MR imaging and pathologic specimen after…
- Trial name
- NCT03560102
- Testing
- Philips Sonalleve® MR-HIFU Breast Therapy System
- Where
- Switzerland
- Volunteers
- 1 people
- Sponsor
- Kantonsspital Winterthur KSW
Breast Neoplasm Malignant Breast Tissue
What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy?
Breast cancer is the most prevalent cancer affecting women. To treat locally advanced breast cancers, neoadjuvant chemotherapy (NACT) is often carried out before surgery to reduce the tumour size to allow breast conservation…
- Trial name
- NCT03501394
- Testing
- Magnetic Resonance Imaging, Histopathological Analysis, Health Questionnaire
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Aberdeen
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
This phase II clinical trial studies how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with advanced, metastatic, or recurrent triple negative invasive breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer
- Trial name
- NCT01151449
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)